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Abstract 
Rationale: Loss of histone macroH2A1 induces appearance of cancer stem cells (CSCs)-like cells in 
hepatocellular carcinoma (HCC). How CSCs interact with the tumor microenvironment and the 
adaptive immune system is unclear.  
Methods: We screened aggressive human HCC for macroH2A1 and CD44 CSC marker 
expression. We also knocked down (KD) macroH2A1 in HCC cells, and performed integrated 
transcriptomic and secretomic analyses.  
Results: Human HCC showed low macroH2A1 and high CD44 expression compared to control 
tissues. MacroH2A1 KD CSC-like cells transferred paracrinally their chemoresistant properties to 
parental HCC cells. MacroH2A1 KD conditioned media transcriptionally reprogrammed parental 
HCC cells activated regulatory CD4+/CD25+/FoxP3+ T cells (Tregs).  
Conclusions: Loss of macroH2A1 in HCC cells drives cancer stem-cell propagation and evasion 
from immune surveillance. 
Key words: hepatocellular carcinoma, histone macroH2A1, adaptive immune system, chemoresistance. 
Introduction 
Hepatocellular carcinoma (HCC) is the second 
leading cause of cancer-related death worldwide [1]. 
In advanced HCC, the liver maintains only a poor 
level of function, which limits patient eligibility for 
surgery. HCC tumors contain a population of cancer 
stem cells (CSCs) that are associated with metastatic 
potential and relapse [2]. These CSCs can self-renew 
and differentiate to give rise to virtually all HCC cell 
types [2]. Interestingly, while CSCs themselves do not 
rapidly proliferate, their progeny have a high 
proliferative capacity, and markedly augment the 
tumor mass. Although conventional chemothera-
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peutics suppress the proliferating cells that comprise 
the bulk of the tumor [3], CSCs are resilient to 
chemotherapy. Consequently, the gold standard HCC 
chemotherapeutic Sorafenib increases the average 
patient survival time by only a few months [4]. It is 
thus imperative to develop therapies that specifically 
target CSCs to enhance patient survival and 
wellbeing. 
HCC typically arises as a result of hepatic injury 
and inflammation. As such, the physiological 
defensive response towards HCC strongly relies on 
the adaptive immune system and its cellular 
constituents: macrophages, natural killer (NK) cells, 
plasma cells, NKT cells, regulatory T cells (Treg) and 
CD4+ and CD8+ T cells [5]. The immune system 
triggers a potent anti-tumor response during HCC 
development: hepatic tumor progression markedly 
increases in T and B-cell-deficient Rag1−/− mice upon 
diethylnitrosamine (DEN)-induced liver injury [6]. 
Moreover, impaired immune surveillance of 
senescent hepatocytes induces HCC development in 
mice, indicating that senescence surveillance is 
important for tumor suppression in the liver [7, 8]. 
CSC-specific avoidance of immune-cell detection and 
destruction might allow tumor relapse [9, 10]; 
whether this is the case in HCC is currently unclear. 
Autocrine/paracrine non-cell-autonomous 
mechanisms govern the interplay between CSCs and 
neighboring cancer, immune and stromal cells and 
regulate CSC expansion and self-renewal in various 
cancers [11-14]. As CSCs have an important role in 
mediating drug resistance following chemotherapy 
and in immune evasion, efforts should be made to 
identify the specific factors secreted by hepatic CSCs 
and determine their influence on neighboring cells 
and the signaling and epigenetic mechanisms that 
control their production. 
We previously demonstrated a link between the 
epigenetic regulatory properties of the histone variant 
macroH2A1 and the emergence of CSCs in HCC [15, 
16]. MacroH2A1 is the largest histone variant in 
nature: it is composed of a domain that is 66% 
homologous to histone H2A, and a C-terminal linker 
that connects the histone fold domain to a macro 
domain. MacroH2A1 can either repress or activate 
transcription in response to growth signals [17]. 
MacroH2A1 exists as two alternatively exon-spliced 
isoforms, macroH2A1.1 and macroH2A1.2 [17]. In 
several cancer types, evidence supports a 
tumor-suppressive role for macroH2A1.1, while the 
role of macroH2A1.2 is dependent on the specific 
cancer context [18]. Histone variants have crucial roles 
in all DNA-template based processes, including 
transcriptional regulation and DNA repair and differ 
from their canonical (H2A, H2B, H3 and H4) 
counterparts in stability, DNA wrapping, and 
possession of specialized domains that regulate access 
to DNA [19]. MacroH2A1 expression is typically low 
in poorly differentiated and aggressive HCC subtypes 
compared to well-differentiated HCC. MacroH2A1 
knockdown in HCC cell lines transforms them into 
CSC-like cells, thus illustrating that absence of 
macroH2A1 mediates cellular stem-like features and 
tumorigenic potential [15, 16]. MacroH2A1 expression 
has also been associated with the pathogenesis of 
multiple cancers [19]. 
Here, we demonstrate that loss of macroH2A1 
expression, as observed in many HCC models, can 
reprogram parental HCC cells to a CSC-like 
chemoresistant phenotype in a paracrine manner. Our 
functional and immunological analyses on the 
macroH2A1-dependent CSC-like secretome suggest 
that this epigenetic pathway might provide an 
under-appreciated link between cancer stemness 
propagation in the tumor microenvironment (TME), 
and tumor-cell evasion from adaptive immune 
surveillance. 
Materials and Methods  
Cell cultures and treatments 
The HepG2 and Huh-7 parental lines (ATCC) 
were cultured in DMEM (1X) supplemented with 10% 
fetal bovine serum (FBS) and 1% 
penicillin/streptomycin. Stable knock-down (KD) of 
macroH2A1 was achieved by lentiviral transduction 
[16]. HepG2 or Huh-7 control cells were exposed or 
not to conditioned media (CM) from macroH2A1 KD 
cells for 24 h. Chemoresistance experiments were 
performed by incubating cells for 72 h with 1 µM 
Sorafenib (SIGMA, Germany), 2 µM Doxorubicin 
(Santa Cruz Biotechnology, USA) or DMSO. Pentose 
phosphate pathway (PPP) inhibition in Huh-7 cells 
was achieved by incubating cells for 24-48 h with 2.5-5 
µM Physcion (Sigma, Germany). Cell proliferation 
was measured by MTT assay [20]. To assess 
population doubling time of HepG2 and Huh‑7 cells, 
suspension of cells containing 300,000 cells/well were 
applied to 6‑well plates. Number of the cells was 
counted every day up to 3 days after plating. 
Metabolomics 
The Huh-7 central carbon metabolism profile 
was studied using ultra-high performance liquid 
chromatography – mass spectrometry (UHPLC-MS) 
to evaluate potential differences in 64 metabolites 
between macroH2A1 KD and control cells 
(Supplemental Table 1). Metabolite extraction: Cell 
pellets were re-suspended in cold extraction solvents 
[methanol/ethanol (1/1, v/v)] spiked with 
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metabolites not detected in un-spiked cell extracts 
(internal standards) and incubated at -20 °C for 1 h. 
The samples were then vortexed and centrifuged at 
18,000 x g, at 4 °C for 5 min. Supernatants were 
collected and kept at 4 °C, while cell pellets were 
re-suspended again in cold extraction solvents and 
incubated at -20 °C for 1 h. Samples were vortexed 
and centrifuged at 18,000 x g, at 4°C for 5 min and the 
supernatants were collected and pooled with the 
previous supernatant samples. Supernatants were 
dried under vacuum, reconstituted in water and 
re-suspended with agitation for 15 min. The samples 
were then centrifuged at 18,000 x g for 5 min at 4 °C 
and transferred to vials for UHPLC-MS analysis. Two 
different quality control (QC) samples were used to 
assess the data quality: 1. a QC calibration sample to 
correct for the different response factors between and 
within batches; and 2. a QC validation sample to 
assess how well the data pre-processing procedure 
improved the data quality. Randomized sample 
injections were performed, with each of the QC 
calibration and validation extracts uniformly 
interspersed throughout the entire batch run. 
Data Pre-Processing: All data were processed 
using the TargetLynx application manager for 
MassLynx 4.1 software (Waters Corp., Milford, USA). 
Data pre-processing generated a list of 
chromatographic peak areas for the metabolites 
detected in each sample injection. An approximated 
linear detection range was defined for each identified 
metabolite, assuming similar detector response levels 
for all metabolites belonging to a given chemical class 
represented by a single standard compound. Data 
normalization was performed as previously described 
[21]. The ion intensities detected for each peak were 
normalized within each sample, to the sum of the 
peak intensities in that sample. There were no 
significant differences (HuH-7: t-test=0.1611) between 
the total intensities used for normalization of the 
groups compared in the study. 
Data Analysis: Once normalized, the 
dimensionality of the complex data set was reduced to 
enable easy visualization of any metabolic clusters in 
the different sample groups. Data reduction was 
achieved by multivariate data analysis, including 
non-supervised principal components analysis (PCA) 
and/or supervised orthogonal partial least-squares to 
latent structures (OPLS) approaches [22]. Univariate 
statistical analyses were also performed to calculate 
the group percentage changes and the unpaired 
Student’s t-test p-value for the following comparison: 
HuH-7 KD vs. HuH-7 CTL. 
Immunoblotting and ELISA 
RayBio® Human Biotin Label Based Antibody 
Arrays - Human L-507 Array, Membrane 
(AAH-BLM-1A-2, RayBio®, US) was used to analyze 
the supernatant (conditioned media) of Huh-7 cells 
(control or macroH2A1 KD), according to 
manufacturer’s instructions. A Human Cytokines 
antibody array membrane (Abcam, Germany) was 
used to analyze the supernatant (conditioned media) 
of HepG2 cells (control or macroH2A1 KD), according 
to manufacturer’s instructions (ab133997, Abcam, 
US). Detection of IL-6 and IL-8 levels in the culture 
media of Huh-7 cells was performed using 
Quantikine® kits (Bio-Techne R&D Systems s.r.o., 
Prague, Czech Republic), according to manufacturer’s 
instructions.  
Nuclei protein fractions from HepG2 and Huh-7 
CTL cells were isolated as previously described [23, 
24]. Primary antibodies were obtained from Active 
Motif (macroH2A1.1 and macroH2A1.2) and Cell 
Signaling Technology (H2B). 
T-cell activation assay 
Peripheral blood mononuclear cells (PBMC) 
were isolated from buffy coats of healthy volunteers 
(University Hospital Brno) by density gradient 
centrifugation using Ficoll. Cell pellets were 
re-suspended in PBS and centrifuged at 200 x g for 15 
min at 20oC. Total T lymphocytes were isolated using 
the Pan T-cell isolation kit (Miltenyi Biotech, 
Germany), according to manufacturer’s instructions. 
T cells fluorescently stained using CD4+–FITC and 
C25+–PE antibodies (Biosciences, Germany) were 
processed for analysis in a BD FACSCantoTM II Flow 
Cytometer (Becton Dickinson, Germany).  
Treg suppression assay 
Treg suppression assay was performed using a 
Treg Suppression Inspector assay, according to 
manufacturer’s instructions (Miltenyi Biotech, 
Germany). CD4+/CD25+/FoxP3+ Tregs purified from 
fresh T cells from healthy donor blood and incubated 
with either CTL media or macroH2A1 KD media for 
the whole length of the assay, were used as 
suppressor cells, and the CD4+/CD25- fraction was 
used as responder cells. To setup the assay, CD4+ 
/CD25+/FoxP3+ were cultured with CD4+/CD25- T 
cells at increasing ratios (1:0, 1:1, 1:2, 1:4, 1:8). As a 
control, CD4+/CD25- responder cells were cultured 
alone. A total of 5×105 CD4+/CD25- responder cells 
labeled with CFSE (Sigma, Germany) were 
co-cultured with 5×105 CD4+/CD25+/FoxP3+ Tregs in 
48-well plates in a volume of 1 ml/well of TexMACS 
medium (Miltenyi Biotech, Germany) supplemented 
with 100 U/ml of penicillin/streptomycin 
(ThermoFisher Scientific, Waltham, USA), and Treg 
Suppression Inspector, composed of anti-biotin 
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MACSiBead™ particles preloaded with biotinylated 
anti-CD2, anti-CD3, and anti-CD28 antibodies 
(Miltenyi Biotech, Germany) for four days. Cells were 
then analyzed in a BD FACSCantoTM II Flow 
Cytometer (Becton Dickinson, Germany). 
RNA-Seq and bioinformatic analyses 
Total RNA was extracted from control and 
macroH2A1 KD Huh-7 cells using TRIzol Reagent 
(ThermoFisher Scientific, Waltham, USA). Indexed 
libraries were prepared from 250 ng purified RNA 
using the NEBNext Ultra II Directional RNA Library 
preparation kit with polyA selection module (New 
England Biolabs, Ipswich, USA). Libraries and input 
RNA samples were quality checked using Fragment 
Analyzer (Advanced Analytical, Ankeny, US). The 
libraries were pooled so that each index-tagged 
sample was present in equimolar amounts. The 
pooled samples then underwent cluster generation 
and sequencing using an Illumina NextSeq 500 
(Illumina, San Diego, US) in a 2 x 75 paired-end 
format. Short reads were aligned against the hg19 
genome assembly using STAR (ver. 2.6.1a). Piled-up 
reads were counted with htseq-count [25]. Read-count 
normalization and comparisons were performed 
using the edgeR R package. Genes were considered 
differentially expressed between groups if their 
expression values significantly differed by ≥2 folds. 
Statistical differences in gene expression were 
assessed by the ANOVA test. Correction for multiple 
test was achieved by the Benjamini-Hochberg 
procedure. The significance threshold was set to 0.05. 
Functional and pathway enrichment analyses were 
performed using the Ingenuity Pathway Analysis 
(IPA, Milan, Italy) software tool. The RNASeq 
profiling data have been deposited to the GEO 
database, with accession number GSE131680. 
Immunohistochemistry 
The Institutional Ethical Review Committee of 
the University Hospitals of Leuven approved the use 
of human HCC samples in this study. A total of 18 
formalin-fixed paraffin-embedded (FFPE) liver 
biopsies from patients with HCC, treated at the 
University Hospitals of Leuven between 2003 and 
2008, were included in this study. Patient 
clinicopathological features and 
immunohistochemistry methods were previously 
described [20, 26]. A further 20 samples from 
explanted livers of patients undergoing liver 
transplantation for HCC at the Royal Free Hospital 
(London, UK) were included (Supplemental Table 2). 
All patients signed informed consent forms for the use 
of the explanted liver tissue for research as part of the 
standard consent process for liver transplantation. 
Immunohistochemical staining on samples from UK 
human cases of encapsulated or non-encapsulated 
HCC was conducted according to previously 
described protocols [24, 26-28], using Abcam 
antibodies (Cambridge, UK) against macroH2A1, 
macroH2A1.1, macroH2A1.2, p16, CD44 or CD4+. 
Immunohistochemical analysis of the cases from the 
University Hospitals of Leuven was performed as 
previously described [29]. Semi-quantitative scoring 
of staining was performed in blind by two expert 
anatomo-pathologists (MVH and FR), as it was 
previously described [24, 26-28]. 
Statistical analyses 
The data represent the means ± s.e.m. 
Comparisons between groups were made using the 
Student’s t-test or the Mann–Whitney U-test, as 
appropriate, using GraphPad Prism Software (version 
5.00 for Windows, San Diego, CA, USA). A P-value 
⩽0.05 was considered statistically significant.  
Results 
Human HCCs with stem-like characteristics 
express low levels of macroH2A1  
High levels of macroH2A1 expression in human 
patients indicate differentiated HCC [23, 30].  
Conversely, macroH2A1 is weakly expressed in 
HCCs with a high level of CSCs (such as 
advanced-stage and sporadic fibrocellular HCC) 
compared to highly differentiated tumors [16]. 
However, we did not previously consider a crucial 
prognostic factor, tumor encapsulation. Encapsulated 
HCCs exhibit a grossly distinct capsule-like fibrous 
tissue surrounding well-differentiated tumors, and 
are associated with a protracted clinical course and 
increased survival [31]. We assessed macroH2A1 and 
CD44 expression by immunohistochemical labeling of 
HCC biopsies from patients with encapsulated or 
non-encapsulated tumors (n=10 per group) (Figure 
1A and B) (Supplemental Table 2). As macroH2A1 
staining was heterogeneous in both tumor groups, we 
applied a semi-quantitative scoring method as 
follows: high (+++), intermediate (++) and low (+) 
nuclear staining intensity (Figure 1C, upper panel). 
We combined this score with a score ranging from 0 to 
100 to define the percentage of cells with defined 
nuclear staining intensity, in any randomly chosen 
field (Figure 1C, lower panel). The same scoring 
procedures were used to define CD44 staining. 
Our analysis confirmed a significant down- 
regulation of macroH2A1 immunopositive cells in 
non-encapsulated compared to encapsulated HCC 
(Figure 1C), regardless of variations in intratissutal 
staining intensity. We also confirmed a negative 
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correlation between CD44 and macroH2A1 
expression: encapsulated tumors displayed weak or 
no CD44 staining, and non-encapsulated tumors 
showed strong CD44 staining (Figure 1B-D). In 
summary, down-regulation/loss of macroH2A1 
histone is associated with human non-encapsulated 
HCC.  
MacroH2A1 knock-down (KD) HCC cells 
up-regulate glycolytic pathways 
We previously showed that macroH2A1 KD 
induces CSC-like cellular architecture, morphology 
and behavior in HepG2 and Huh-7 HCC cell lines 
[16]. Central carbon cell metabolism (CCM) supports 
multiple physiological processes including 
biosynthesis, amino acid homeostasis, epigenetic 
maintenance, and redox defense [32]. CCM converts 
carbohydrates into metabolic precursors via three 
main pathways: glycolysis, the PPP and the citric acid 
cycle. CSCs are able to reprogram CCM to cater 
disease needs [33]. Huh-7 is more aggressive than 
HepG2 cells, in vitro and in vivo, and the two cell lines 
have a different genetic make-up [30, 34-36]. 
Moreover, control HepG2 and Huh-7 cells display 
similar levels of macroH2A1.2 isoform protein 
expression; however Huh-7 cells display higher 
macroH2A1.1 basal protein expression compared to 
HepG2 (Figure 2A). We have previously shown that 
macroH2A1 KD in HepG2 cells leads mainly to lipid 
metabolism reprogramming – with massive Acetyl- 
coA accumulation – and to a lesser extent to activation 
of glycolytic pathways [15]. Here we aimed to 
understand the central CCM profiles required to 
target CSCs using Huh-7 cells, which is instead one of 
the most aggressive HCC cell lines [30, 34-36]. We 
analyzed the endogenous metabolic profiles of control 
and macroH2A1 KD Huh-7 cells using an optimized 
UHPLC-MS platform that can profile 64 metabolites 
involved in CCM (Table S1). We initially performed 
an Orthogonal Partial Least Squares Classification for 
High Dimensional Data (OPLS-DA) analysis of 
control (n=7) and KD (n=7) cells to visualize any 
differences between the two groups (Figure S1A). This 
analysis identified a clear clustering of samples 
according to the experimental group (Figure S1A). We 
then generated a loading scatter plot based on the 
OPLS-DA analysis to identify the variables 
underlying this differential clustering. The 
metabolites lying away from the plot origin (having 
the strongest impact on the model) included 
nucleotides, redox/electron carriers and 
carbohydrates (Figure S1B). 
We then conducted a univariate data analysis to 
calculate and compare (Student’s t-test) the group 
percentage change and fold change for each 
individual metabolite between control and KD Huh-7 
cells. Significant differences were found between 17 of 
the 64 tested metabolites in KD cells compared to 
control Huh-7 cells. Specifically, the levels of redox 
electron carriers (NADP, NADPH) and nucleotides 
(including ATP) were increased in Huh-7 KD cells 
compared to control cells (Figure S1C-D). These 
changes are consistent with increased activation of 
glycolytic branches that generate reduced forms of 
electron carriers and ATP in CSCs, and hyper- 
activation of the PPP [37] (Figure S2). Consistent with 
PPP activation, the fructose-6-phosphate (F6P)/ 
glucose-6-phosphate (G6P) ratio was significantly 
decreased in HuH-7 KD compared to control cells 
(Figure S1C-D). In summary, these data suggest that 
macroH2A1 KD-induced CSC-like cells display 
activated glycolytic branches, particularly in the PPP. 
MacroH2A1 KD HCC cells can confer 
chemoresistance to parental HCC cells in a 
paracrine manner 
MacroH2A1 modulates the transcriptional 
activity of cytokine/chemokine genes such as IL-6, 
IL-8, CXCL1 and CXCL6 [38], which fine-tune CSC 
homeostasis [39]. As modulated glycolytic activity is 
linked to altered cytokine production in immune cells 
[40], we hypothesized that the pro-glycolytic 
metabolic profile of macroH2A1 KD Huh-7 cells 
would change the cancer-associated secretome and 
affect the phenotype of neighboring parental HCC 
cells. To test our paracrine hypothesis, we exposed 
control Huh-7 cells to the CM of macroH2A1 KD cells 
for 72 h (Figure 2B). Consistent with previous studies 
[16], cell proliferation was lower in macroH2A1 KD 
and macroH2A1 KD CM-exposed Huh-7 cells, 
compared to control, non-exposed cells (Figure 2C). 
Doxorubicin (an anthracycline antibiotic) and 
Sorafenib (a multi-tyrosine kinase inhibitor) are 
commonly used chemotherapeutics for advanced 
HCC. We incubated control, macroH2A1-KD, and 
CM-exposed Huh-7 cells with 2 µM Doxorubicin or 1 
µM Sorafenib for 72 h, and found that both 
macroH2A1 KD and CM from KD cells could confer 
resistance to drug-induced cell proliferation inhibition 
(Figure 2C). Population doubling analyses mirrored 
the cell proliferation analyses (Figure 2D). However, 
when we incubated control, macroH2A1-KD, and 
CM-exposed HepG2 cells with 2 µM Doxorubicin or 1 
µM Sorafenib for 72 h, we found that the CM from 
macroH2A1 KD was not able to confer resistance to 
drug-induced cell proliferation inhibition in this cell 
line (Figure S3A, B). These data support that 
macroH2A1-dependent chemoresistance can be 
conferred in a paracrine fashion in Huh-7 cells but not 
in HepG2 cells. 
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Figure 1. MacroH2A1 and CD44 expression levels negatively correlate in encapsulated/non-encapsulated HCC from explanted livers of 
patients undergoing liver transplantation. Representative immunohistochemical staining of macroH2A1 (A) or CD44 (B) in encapsulated versus 
non-encapsulated (metastatic) tumors. (C, D) Semi-quantitative scoring of cases as in A and B, based on high (+++), intermediate (++) and low (+) nuclear staining 
intensity, and the score of cells with the defined nuclear staining intensity from 0 (low) to 100 (high). N = 10 encapsulated tumors, N=10 non-encapsulated tumors. 
* p < 0.05; ** p < 0.01. 
 
Figure 2. Huh-7 macroH2A1 KD cells confer chemoresistance to parental cells in a paracrine manner. A. Nuclear fractions isolated from CTL HepG2 
or Huh-7 cells, were processed for immunoblotting with anti-macroH2A1.1, anti-macroH2A1.2 and anti-H2B antibodies. B. Three experimental conditions: control 
(CTL), KD and CTL cells plus KD conditioned medium (CM). C. MTT assay in CTL, KD or CTL + CM cells incubated with or without vehicle (DMSO), 2 µM 
Doxorubicin (Doxo) or 1 µM Sorafenib for 72 h. Data represent the mean cell proliferation ± s.d. relative to CTL cells at 24 h. N=4. D. Population doubling time in 
CTL, KD or CTL + CM cells incubated with or without vehicle (DMSO), 2 µM Doxorubicin (Doxo) or 1 µM Sorafenib for 72 h. Data represent the mean cell 
proliferation ± s.d. N=3.*P < 0.05, ** P < 0.01 relative to CTL; & P < 0.05,& & P < 0.01 relative to Doxo; $ P < 0.05,$ $ P < 0.01 relative to Sorafenib. 
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Figure 3. Functional enrichment of commonly differentially expressed genes in control (CTL), macroH2A1 knockdown (KD) and conditioned 
media (CM) Huh-7 cells. A. Heatmap of counts per million (cpm) values of commonly differentially expressed genes in KD vs CTL and CM vs CTL. B. Plot 
showing the enrichment results of KD vs CTL (top) and CM vs CTL (bottom) comparisons. Bar lengths represent the –log(p-value) of the enriched functions. The 
orange line indicates the statistically significant threshold. Asterisks denote functions implicated in inflammatory and immune responses. 
 
MacroH2A1 KD HCC cells can 
transcriptionally reprogram parental HCC 
cells and produce a cytokine-depleted medium 
We next used RNA-Seq to gain deep mechanistic 
insight into the distinct functions of macroH2A1 KD 
and (CM-)exposed Huh-7 cells. A heatmap drawn for 
the 202 commonly differentially expressed genes 
between the three groups revealed a similar 
transcriptomic profile between KD and CM, 
compared to the control condition (Figure 3A).  
The transcriptomic profile similarity between 
CM and KD in comparison to CTL was also confirmed 
by measuring the Euclidean distance between 
centroids of clusters obtained by K-means algorithm 
(data not shown, [41]).  
Assessment of differentially expressed genes for 
Huh-7 macroH2A1 KD or Huh-7 CM KD versus CTL 
showed no transcriptional overlap between the 
different Huh-7 cell lines. 783 and 987 genes were 
significantly and differentially expressed (|FC|≥2, 
adj. p-value ≤0.05) over a total number of 26,439 
screened genes, in macroH2A1 KD or CM KD versus 
control cells, respectively (Figure S4A, B). 
Interestingly, the significantly enriched genes, 
over-represented in KD and CM-exposed cells 
compared to control cells, were implicated in a 
number of functions and diseases that were also 
shared between CM versus CTL comparisons (Figure 
3B). Specifically, Ingenuity pathway analysis (IPA) 
identified categories of cancer, gastrointestinal 
diseases, lipid metabolism, cell-to-cell signaling, 
nucleic acid metabolism, cell death & survival and 
others, in common between KD versus CTL and CM 
versus CTL (Figure 3B). These data support a 
paracrine modulation of gene expression by 
macroH2A1 KD in HCC cells. 
Although Huh-7 cells were not exposed to any 
treatment other than the CM from KD cells, IPA 
revealed an enrichment in the categories of 
inflammatory disease, immune-cell trafficking (KD 
versus CTL), and cell mediated-immune responses 
(CM versus CTL) (Figure S5). As inflammatory and 
immune responses are chiefly mediated via secreted 
factors, we performed a quantitative analysis of a 
commercial comprehensive panel of 507 human 
cytokines, chemokines, adipokine, growth factors, 
angiogenic factors, proteases, soluble receptors and 
soluble adhesion molecules, detectable in Huh-7 CTL 
and macroH2A1 KD cell supernatants. Figure 4A 
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shows a principal component analysis (PCA) which 
identified a clear clustering of samples according to 
the experimental group. Setting a fold-change barrier 
to 1.2, and the significance level to ≤0.05 
(Benjamini-Hochberg adjusted p-value), we detected 
94 differentially expressed factors (Figure 4B). 
Stunningly, with the exception of GDF15 and 
Lipocalin 2 (LCN2) that were upregulated, the 
remaining secreted factors were underrepresented in 
the supernatant of macroH2A1 KD Huh-7 cells 
(Figure 4B). In contrast, no changes were observed in 
HepG2 cells, between CTL and macroH2A1 KD, upon 
quantitative analysis of a panel of most representative 
48 human cytokine/chemokines (Figure S6). To 
ascertain whether the decreased levels of secreted 
factors in the macroH2A1 KD Huh-7 secretome were 
linked to their reprogrammed metabolism, namely 
PPP activation (Figure 2, Figure S2), we preincubated 
control and macroH2A1 KD cells for 24-48 h with 
2.5-5 µM Physcion — an effective inhibitor of the third 
enzyme of the PPP [42]. We then assessed the levels of 
the two key pro-inflammatory cytokines, IL-6 and 
IL-8 (CXCL8) in the supernatants by ELISA (Figure 5). 
We confirmed downregulation of IL-6 and IL-8 
protein levels in the macroH2A1 KD supernatant 
compared to control cells (Figure 5A, B). Physcion 
restored IL-6 and IL-8 levels in the KD cell 
supernatant upon 48 h incubation with a 5 µM dose, 
whereas no effect was seen in control cells (Figure 5A, 
B). These findings suggest that macroH2A1- 
dependent decreased IL-6/IL-8 secretion may be 
dependent on PPP activation. 
 
 
Figure 4. Secretome analysis. A. Principal Component Analysis applied to expression profiles of 507 human cytokines, chemokines, adipokine, growth factors, 
angiogenic factors, proteases, soluble receptors and soluble adhesion molecules in KD and CTRL cells. B. Heatmap representation of 94 differentially expressed 
molecules between KD (blue group) and CTRL cells (red group). Expression values were scaled between -1 and 1, where positive numbers were represented in tones 
of red, blue otherwise. 
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Figure 5. ELISA analysis of cytokine levels in Huh-7 macroH2A1 knockdown (KD) compared to control (CTL) cells. A-B. CTL and KD cultured 
cells were treated with Physcion (2.5 and 5 µM) for 24 h or 48 h or untreated. IL-6 (A) or IL-8 (B) or levels (in pg/ml) were measured in the cell supernatants using 
commercial ELISAs. N = 3. *p < 0.05, **p < 0.01 compared to control untreated cells. 
 
HCC harboring low macroH2A1 expression 
displays decreased CD4(+) lymphocyte 
infiltration  
The overall cytokine/chemokine depleted 
medium of macroH2A1 KD CSC-like cells led us to 
hypothesize that loss of macroH2A1 might trigger 
pleiotropic effects that help CSCs evade the defensive 
immune response in a paracrine manner. 
Consistently, running IPA on the Huh-7 secretome 
(Figure 4), we inferred that this cytokine depletion 
would inhibit the process of T cell 
development/maturation (Figure 6A). Surprisingly, 
the changes in the secretome in Huh-7 macroH2A1 
KD cells is largely independent on macroH2A1–
dependent transcriptional regulation: through 
integrated transcriptomic and secretomic analyses we 
detected significant concordance between 
differentially expressed genes and differential 
expression of the corresponding secreted factors only 
in 10 over 94 factors (CCL3, CXCL9, HBEGF, IL7R, 
INHBA, MMP12, MMP24, PDGFB, PDGFD, TGFB3, 
TLR3) (Circos plot, Figure 6B).  
Local immune responses in patients with HCC 
are restrained by tumor and circulating 
CD4+/CD25+/FoxP3+ Tregs, which suppress effector 
CD4+ T-cell activity and proliferation. Tregs are the 
predominant cell-type involved in HCC immune 
escape [43]. Consequently, compromised lymphocyte 
infiltrates (namely, tumor infiltrating lymphocytes; 
TILs) are observed in HCC [44]. Histological 
examination of encapsulated and non-encapsulated 
human HCC did not reveal any differences in total 
lymphocyte infiltration, regardless of tumoral or 
peri-tumoral localization (Figure S7A). 
We then examined whether reduced macroH2A 
levels correlate with a decreased frequency of CD4+ T 
cells specifically, or an increased presence of CD25+ 
TILS. Here, we used a previously described cohort 
[26] that we classified into two groups: patients with 
poorly differentiated HCC and low macroH2A1 
expression; and patients with well-differentiated HCC 
and high macroH2A1 expression (Figure 7).  
Immunohistochemical staining against CD25+ T 
cells revealed an increased tumoral presence in poorly 
differentiated versus well-differentiated tumors; the 
intra-tumoral CD4+ cell content was unchanged 
between the two HCC groups (Figure 7). 
Interestingly, a decreased presence of CD4+ cells was 
observed in the peritumoral area of poorly versus 
well-differentiated HCC (Figure S7B). These data 
demonstrate that aggressive HCC expressing low 
levels of macroH2A1 exhibits high levels of 
intra-tissue TILS expressing the CD25+ Treg marker 
and a decreased adaptive immune response. 
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Tregs mediate their suppressive 
function not only through cell-to-cell 
contact, but also via soluble mediators that 
provide a positive feedback loop for 
immune suppressive mechanisms by 
generating inducible Tregs cells from 
CD4+/CD25−T effector cells [43]. Therefore, 
we investigated the potential of macroH2A1 
KD CSCs to activate CD4+/CD25+/FoxP3+ 
Tregs. We isolated fresh T cells from healthy 
donor blood and incubated them for 72 h 
with either CTL media or KD media. Using 
the flow cytometry gating strategy depicted 
in Figure S10, we observed a significant 
increase in the frequency of activated 
CD4+/CD25+/FoxP3+ Tregs upon treatment 
with KD media compared to control media 
(Figure 8). This increase was paralleled by a 
decrease in CD4+/CD25-/FoxP3+ T cells, 
indicating that conditioned media form KD 
cells triggers Treg generation from these 
precursors in the T cell pool. Altogether 
these data suggest that Tregs are activated in 
a paracrine manner by macroH2A1 KD HCC 
cells. Interestingly, pre-treatment of Huh-7 
CD and macroH2A1 KD cells with PPP 
inhibitor Physcion (5 µM, 48h) generated a 
conditioned medium that nearly completely 
suppressed the frequency of activated 
CD4+/CD25+/FoxP3+ Tregs, while massively 
increasing in parallel the number of 
CD4+/CD25+/FoxP3- T cells (Figure 8). 
Physcion also significantly inhibited the 
formation of the pools of CD4+/CD25-/ 
FoxP3- and CD4+/CD25-/FoxP3+ T cells 
(Figure 8). The functionality of CD4+/CD25+ 
/FoxP3+ Tregs was also analyzed in 
carboxyfluorescein succinimidyl ester 
(CFSE)-based suppression assays. 
Concurrent with co-incubation with CTL or 
KD media, CFSE-labeled CD4+/CD25- T 
responder cells were mixed with 
CD4+/CD25+/FoxP3+ Tregs in presence of 
Treg suppression inspector (anti-Biotin 
MACSiBead™ particles loaded with 
biotinylated CD2, CD3, and CD28 
antibodies), and then proliferation rate of 
responder cells was measured. We did not 
detect differences in the suppressive activity 
of Tregs from the CTL or the KD group 
(Figure S11). In summary, media produced 
from HCC cells KD for macroH2A1 
harboring lead to an expansion in the 
number of activated Tregs, without 
alterations in their suppressive function. 
 
 
Figure 6. (A) Activity inference of the T cell development/maturation biological process by 21 
out of the 94 differentially expressed molecules between KD and CTRL cells. The process is 
colored in blue, since its activity is predicted by IPA to be globally reduced in KD cells. Edges 
are colored (i) in blue, when the fold-regulation of the participating molecules to the process is 
coherent with the activity inference, (ii) in yellow, when there is inconsistency and (iii) gray 
when it is not possible to infer the kind of participation (activation, arrow or inhibition, 
dead-end arrow) of a molecule to the overall process. (B) Circos plot representing (from 
outer to the innermost circle) the 94 molecules, their chromosomal location, their 
fold-regulation values in the RNA-Seq experiment, and their fold-regulation values in the 94 
panel of 507 secreted molecules. Genes were linked by colored bands, if belonging to the same 
biological process: orange (T cell response), green (activation of neutrophils) and violet 
(recruitment of neutrophils). 
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Figure 7. Aggressive hepatocellular carcinoma (HCC) with reduced macroH2A1 expression displays increased CD25+infiltration. 
Immunohistochemical staining for macroH2A1, CD4 and CD25 in poorly differentiated (n = 18) and well-differentiated (n = 16) HCC, from a previously characterized 
cohort [26]. Magnification, 20 X. Black scale bars indicate 100 µM. The lower panels show the mean number of cells counted in 10 high-power fields (HPF) performed 
by a pathologist blinded to the HCC differentiation categories. *p < 0.01 compared to well differentiated. 
 
Figure 8. MacroH2A1 KD conditioned media trigger CD4+/CD25+/FoxP3+ Treg cells expansion. A. T cells isolated from peripheral blood mononuclear 
cells of healthy volunteers were exposed to the culture media taken from CTL cells, macroH2A1 KD cells or CTL cells exposed to the conditioned media (CM) of 
KD cells. All cell lines were pretreated, or not, with PPP inhibitor Physcion (Phy, 5 µM, 48h). The T cells were activated and stained with CD4+, CD25+ and FoxP3+ 
specific antibodies before flow cytometry. Results are expressed as the percentage (%) of the parental population. N = 8; p < 0.05, ** p < 0.01. *** p < 0.001, 
comparisons as indicated. 
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HCC harboring low macroH2A1 expression 
displays decreased cellular senescence 
MacroH2A1 modulates the transcriptional 
activity of IL-6 and IL-8 [38], and these cytokines are 
important effectors of the senescence associated 
secretory phenotype (SASP) [7]. SASP renders cells 
vulnerable to immune-mediated clearance [7]. 
Therefore, we sought to determine if altered 
macroH2A1 isoform (macroH2A1.1 and 
macroH2A1.2) levels in HCC patient tissue samples 
correlate with altered frequency of tumor resident 
senescent cells. We found that a significantly higher 
number of cells immunopositive for β-galactosidase 
(β-gal), a key marker of cellular senescence, paralleled 
the progression of liver disease (control < cirrhosis < 
HCC) and the increased immunopositivity for 
macroH2A1 isoforms in a cohort of patients bearing 
differentiated/encapsulated tumors that we 
previously described [23, 24] (Figure S8). Moreover, 
p16 has been identified as main player in the cellular 
senescence response in the liver cellular senescence 
program, which in turn is involved in tumour 
immune surveillance [7, 8]. Here we found that p16 
was expressed at lower levels in the previously 
examined liver biopsies of patients with poorly 
differentiated HCC and low macroH2A1 expression 
compared to those with well differentiated HCC and 
high macroH2A1 expression [26] (Figure 7, Figure S9). 
Altogether, these immunohistochemistry data suggest 
that macroH2A1 expression positively correlated with 
cellular senescence in human liver. Moreover, cellular 
senescence phenotype correlates positively with HCC 
differentiation. 
Discussion  
A high presence of CSCs in the liver of patients 
with HCC is associated with HCC relapse and 
metastasis [2]. Here, we show for the first time that 
liver CSC-like cells can reprogram neighboring HCC 
cells into other CSC-like cells that can evade the 
adaptive immune system via a combination of 
epigenetic (macroH2A1) and paracrine mechanisms. 
MacroH2A1 is a marker of well-differentiated HCC 
and of non-tumor/tumor liver tissue senescence [23, 
24]; however, our previous and current data suggest 
that macroH2A1 expression is dramatically decreased 
or absent in a wide range of independent 
poorly-differentiated human HCCs [16], although the 
correlation between macroH2A1 immunostaining and 
HCC encapsulation that we found needs validation in 
a larger cohort. What triggers macroH2A1 
down-regulation and subsequent macroH2A1- 
dependent transformation of HCC cells into CSC-like 
cells remains unknown. Previous evidence suggest 
that loss of macroH2A1 might promote a relaxed 
chromatin state that is poised for chromatin 
remodeling to enhance accessibility to 
pro-inflammatory transcription factors (NF-κB), and 
re-expression of reprogramming genes that together 
might lead to a CSC-like phenotype [17, 45, 46]. 
The tumor secretome consists of diffusible 
factors derived from CSCs, cancer cells and the 
surrounding stroma that determine cancer 
progression. Proteomic analysis of pancreatic CSCs 
previously revealed 72 differentially regulated 
proteins compared to the parental cells [47]. To the 
best of our knowledge, the liver CSC secretome has 
not been studied. Our analysis of a panel of 507 
human cytokines, chemokines, adipokine, growth 
factors and other soluble molecules in Huh-7 HCC 
cells with macroH2A1 KD revealed a significant 
down-regulation of 92 out of 94 differentially 
expressed molecules (98%), including IL-6 and IL-8. 
The expression levels of these interleukins are under 
the specific control of macroH2A1.1 isoform – and not 
macroH2A1.2 - [38]; we found macroH2A1.1 
expressed at higher levels in Huh-7 compared to 
HepG2 cells. HepG2 cells do not produce IL-6 (Figure 
S6, [34]). Interestingly, secretomic effects were not 
observed in HepG2 cells KD for macroH2A1. Also, 
macroH2A1 KD HepG2 cells, unlike Huh-7 cells, were 
unable to transfer chemoresistance paracrinally, 
which might be consistent with lower levels of 
macroH2A1.1 [38] in this cell line. HepG2 express a 
wild type tumor suppressor p53, while Huh-7 cells 
express a mutant dominant negative p53 (Y220C) [48]. 
p53 mutations are frequent in human HCC and are 
associated to a shorter survival rate compared to the 
one of wild type p53 carriers [49]; they are also major 
components in the establishment of CSC entity [50]. 
HepG2 and Huh-7 cells KD for macroH2A1 present 
also metabolic differences: while both cell lines 
display increased glycolytic pathways, a more 
significant upregulation of pentose phosphate 
pathway (PPP) with an increased abundance of redox 
electron carriers (NADP, NADPH) is specifically 
observed in Huh-7 ([15], this study), while an 
increased intracellular acetyl-CoA and lipid 
accumulation is specifically observed in HepG2 ([15], 
this study). p53 is a strong inhibitor of PPP: p53 
protein binds to glucose-6-phosphate dehydrogenase 
(G6PD), the first and rate-limiting enzyme of the PPP, 
and prevents the formation of the active dimer [51]. 
Cancer-associated p53 mutants lack the 
G6PD-inhibitory activity [51]. Pre-malignant 
senescent hepatocytes produce SASP that renders 
these cells vulnerable to immune-mediated clearance 
[7]. Our working hypothesis, supported by the data 
on PPP-dependent chemokine-cytokine production, is 
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that CSC-like macroH2A1 KD Huh-7 cells, which are 
p53 mutant and thus display an over-activated PPP, 
are able to produce an “anti-SASP” – depleted in IL-6, 
IL-8 and other effectors, triggering a potential 
mechanism of immune evasion. Consistent with our 
data, macroH2A1-depleted IMR90 cells do not 
senesce in response to SASP factor-containing 
conditioned media from senescent cells, and do not 
activate SASP genes [38]. It is also possible that 
over-activated PPP and deficient macroH2A1 
expression trigger positive epistatic effects on the 
secretome of HCC cells. 
How macroH2A1 KD induces general inhibition 
of secreted factors in HCC cells? Surprisingly, 
integrated transcriptomic and secretomic analysis 
uncovered a low degree of significant concordance 
between mRNA and protein expression levels, ~11% 
(10 out of 94 secreted factors). Cytokine expression 
and production is typically regulated by extensive 
post-transcriptional regulation [52, 53]. Moreover, 
cellular perturbations such as endoplasmic reticulum 
stress, oxidative stress and DNA damage coordinately 
regulate macroH2A1-dependent production of IL-6 
and IL-8 upon K-Ras-dependent oncogenic 
transformation of fibroblasts [38]. The elucidation of 
the transcription/post-transcriptional mechanisms 
leading to the observed cytokine/chemokine 
depletion in macroH2A1 KD-induced CSC-like cells 
warrants further studies. Regardless, the 
cytokine-depleted secretome is related to immune 
evasion. While elevated levels of cytokines produced 
by tumor cells enhance CSC proliferation and the 
differentiation [39], our data suggest the possibility 
that decreased levels of cytokines produced by 
CSC-like cells might favor quiescence, pluripotency 
and chemoresistance - properties that are 
transcriptionally programmed into neighboring 
cancer cells. If this holds true, interventions for 
general neutralizations of chemokines/cytokines 
within the tumor parenchyma might be ineffective on 
the CSC extracellular niche. 
Given the rarity of CSCs within the HCC mass 
[3], it will prove challenging to obtain spatially 
resolved data about the gradients of cytokine and 
chemokine levels in vivo. Technological advancements 
to profile low-molecular-mass proteins are required 
for an unbiased full characterization of the CSC 
secretome. Our findings provide evidence that the 
macroH2A1-dependent CSC-like secretome depleted 
in severable immune mediators leads to 
CD4+/CD25+/FoxP3+ Treg expansion, without 
changes in their suppressive activity, and 
simultaneous curtailment of CD4+CD25-/FoxP3+ T 
cells in human T lymphocyte pools. Treg 
development is classically dependent on IL-2 [54]. 
IL-2 levels were unchanged in macroH2A1 KD 
CSC-like cells (data not shown). Noteworthy, the only 
two secreted factors augmented in the conditioned 
medium from CSC-like cells were GDF15 and 
lipocalin-2. Both factors can promote CD4+/CD25+/ 
FoxP3+ Treg activation, CSC-like properties and 
immune escape [55-59]. Our data thus suggest the 
existence of a complex scenario where the 
macroH2A1 KD-induced CSC-like cells inhibit T cell 
maturation through downregulation of secreted 
immune mediators (Figure 6A), in concert with 
CD4+/CD25+/FoxP3+ Treg expansion due to the 
increased secreted levels of GDF15 and/or lipocalin-2.  
We provide also data that blocking the 
hyperactivation of PPP in macroH2A1 KD Huh-7 cells 
using PPP specific inhibitor Physcion led to 
restoration of downregulated cytokines (IL-6, IL-8) 
and nearly completely suppressed CD4+/CD25+/ FoxP3+ Tregs, suggesting a previously unappreciated link between energy metabolism and chemokine/cytokine production in HCC cells.  
During tissue injury, antigen‐specific 
CD4+/CD25- T cells participate in the control of tissue 
homeostasis in concert with CD8+ T cells, 
macrophages, and NK cells at the inflammatory site. 
Genetic experiments have revealed that functional 
senescence surveillance is dependent on an intact 
adaptive immune response. In CD4+ knockout mice, 
the immune clearance of premalignant senescent 
hepatocytes is abrogated, favoring HCC development 
[7]. We propose that the observed decreased 
recruitment of CD4+ T cells in macroH2A1-deficient 
HCC foci contributes, at least in part, to adaptive 
immune system evasion. A limitation of our study is 
that it does not address the complex mixture of 
non-transformed cell types and the extracellular 
matrix of the TME, as we focus only on major HCC–
CSC and CSCs–T lymphocyte cell-cell crosstalk. 
Further work in 3D tissue models, which might allow 
microvasculature development and quantitative 
assessment of cell-cell and cell-drug interactions in a 
physiologically realistic TME, is required to confirm 
these findings. Approaches aiming at targeting 
cellular metabolism in conjunction with 
chemotherapeutic drugs [60], or ablating CD44 
expression to inhibit glycolysis and the PPP [61], or 
modulating T cells activity through optogenetics [62], 
are innovative strategies that might be useful to treat 
macroH2A1-negative aggressive HCCs. 
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